$MCK — AVOID 📊 | 6 MONTHS THESIS

$MCK — AVOID 📊 | 6 MONTHS THESIS 🎯 Q1 2026 | Rev $96.3B | EPS $11.69 vs $11.57 🟢 💡 Consensus views the stock as steady, but the market may be overestimating pricing power and underestimating competitive and regulatory risks. The 1% EPS beat does not change the low-growth trajectory, and the stock’s slight discount to its own historical PE is offset by a premium to more reasonably valued peers. 📉 Reward/risk: 0.78:1 🏢 Business Quality: 7 — Dominant pharmaceutical distributor with essential scale and steady cash flows, but thin margins, opioid litigation overhang, and potential disintermediation limit quality./10 📊 Valuation: fair — PE 19.6x (slightly below 5-year median 20.1x but above peers like CAH at ~17x and ABC at ~16x); EV/EBITDA ~13x; FCF yield ~4-5%. 🔮 Catalyst: Next quarterly earnings release and guidance update 📊 Our read: AVOID. Full analysis → https://stockduty.xyz/s/MCK0623

🎯 Q1 2026 | Rev $96.3B | EPS $11.69 vs $11.57 🟢